• 1. 首都醫(yī)科大學附屬北京同仁醫(yī)院普外科(北京100730)2. 首都醫(yī)科大學附屬北京友誼醫(yī)院普外科3. 首都醫(yī)科大學附屬北京友誼醫(yī)院病理科4. 衛(wèi)生部結核病控制中心參比實驗室;

為探討抑凋亡基因bcl-2蛋白表達在乳腺癌中的意義，應用免疫組織化學的方法(SP法)，對125例浸潤性乳腺癌患者的石蠟包埋組織切片中bcl-2、雌激素受體(ER)、孕激素受體(PR)及p53基因的表達產(chǎn)物進行檢測。結果： bcl-2蛋白在浸潤性導管癌中的表達為63.3%，而在浸潤性小葉癌中為88.9%，二者間的差異有顯著性意義(Ｐ＜0.001)； 在浸潤性導管癌中，bcl-2蛋白的表達與原發(fā)癌大小及腫瘤分級呈負相關(Ｐ＜0.05)，與ER、PR的表達呈正相關(Ｐ＜0.001)，與p53的表達呈負相關(Ｐ＜0.001)。但未發(fā)現(xiàn)bcl-2表達與腋窩淋巴結轉移有統(tǒng)計學上的顯著性差異。結論： 乳腺癌bcl-2蛋白表達與預后良好的生物學指標有一致性，與預后不良的指標呈反向表達，提示bcl-2蛋白表達可作為乳腺癌的生物學指標，在乳腺癌的病理及臨床中有一定意義。

引用本文： 林清,高東宸,張長淮,盧小梅,李衛(wèi)民. 乳腺癌中bcl-2蛋白表達的意義. 中國普外基礎與臨床雜志, 1999, 6(5): 263-265. doi: 復制

版權信息： ?四川大學華西醫(yī)院華西期刊社《中國普外基礎與臨床雜志》版權所有，未經(jīng)授權不得轉載、改編

1. Shunzo K, Hirotaka I, Yukashi I, et al. Clinical significance of bcl-2 gene expression in human breast cancer tissue. Breast Cancer Res Treatment, 1997; 42(2)∶173.
2. Lee WY, Jin YT, Tzeng CC, et al. Reciprocal expression of bcl-2 and p53 in breast ductal carcinoma. Anticancer Research, 1996; 16(5A)∶3007.
3. Julia MWG, John FRR, Ian OE, et al. Immunocytochemical localization of bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer, 1994; 59(5)∶619.
4. Hellemans P, Van Dam PA, Weyle J. Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer, 1995; 72(2)∶354.
5. Gasparini G, Barbareschi M, Doglioni C, et al. Expression of bcl-2 protein predicts efficacy of adjuvant treatment in operable nodepositive breast cancer. Clin Cancer Res, 1995; 1(2)∶189.
  1. 1. Shunzo K, Hirotaka I, Yukashi I, et al. Clinical significance of bcl-2 gene expression in human breast cancer tissue. Breast Cancer Res Treatment, 1997; 42(2)∶173.
  2. 2. Lee WY, Jin YT, Tzeng CC, et al. Reciprocal expression of bcl-2 and p53 in breast ductal carcinoma. Anticancer Research, 1996; 16(5A)∶3007.
  3. 3. Julia MWG, John FRR, Ian OE, et al. Immunocytochemical localization of bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer, 1994; 59(5)∶619.
  4. 4. Hellemans P, Van Dam PA, Weyle J. Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer, 1995; 72(2)∶354.
  5. 5. Gasparini G, Barbareschi M, Doglioni C, et al. Expression of bcl-2 protein predicts efficacy of adjuvant treatment in operable nodepositive breast cancer. Clin Cancer Res, 1995; 1(2)∶189.